EICHORCondition: Dyskinesias · Parkinson Disease · Sponsor: Bukwang Pharmaceutical
This is a two-part, double-blind, placebo-controlled, randomized, multicenter Phase 2 clinical trial of JM-010 in patients with Parkinson's Disease.
This description comes directly from the study's public registry record.
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Inclusion Criteria: * Is able to read, understand, and provide written, dated informed consent prior to Screening Visit. * Is male or female, between 18 and 85 years of age at Screening Visit. * Is diagnosed with idiopathic PD that meets UK Parkinson's Disease Society (UKPDS) Brain Bank Clinical Diagnostic Criteria * Has experienced dyskinesia * Has stable peak-effect dyskinesia * Has more than one hour of "ON" time with troublesome dyskinesia Exclusion Criteria: * Has undergone surgery for the treatment of PD * Has a current diagnosis of Substance Use * Has psychiatric diagnosis of acute psychotic disorder or other psychiatric diagnoses * Has current seizure disorders requiring treatment with anticonvulsants. Other criteria related to other medical conditions to be referred to the protocol.
Reproduced word-for-word from the public registry record — the study team can answer questions about it.
| Bukwang Investigator site | Miami, Florida, United States | — |
| Bukwang Investigator site | Detroit, Michigan, United States | — |
This study lists sites in the areas below. Each link shows other recruiting studies near that city, from the public registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04377945